These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36347937)

  • 21. Establishment of patient-derived cancer organoids for drug-screening applications.
    Driehuis E; Kretzschmar K; Clevers H
    Nat Protoc; 2020 Oct; 15(10):3380-3409. PubMed ID: 32929210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.
    Jayawickrama SM; Ranaweera PM; Pradeep RGGR; Jayasinghe YA; Senevirathna K; Hilmi AJ; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2045. PubMed ID: 38522008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
    Lakshmanachetty S; Balaiya V; High WA; Koster MI
    Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
    Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
    Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling.
    Dzobo K; Rowe A; Senthebane DA; AlMazyadi MAM; Patten V; Parker MI
    OMICS; 2018 Dec; 22(12):733-748. PubMed ID: 30571609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
    Facompre ND; Rajagopalan P; Sahu V; Pearson AT; Montone KT; James CD; Gleber-Netto FO; Weinstein GS; Jalaly J; Lin A; Rustgi AK; Nakagawa H; Califano JA; Pickering CR; White EA; Windle BE; Morgan IM; Cohen RB; Gimotty PA; Basu D
    Int J Cancer; 2020 Dec; 147(11):3236-3249. PubMed ID: 32478869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
    Kijima T; Nakagawa H; Shimonosono M; Chandramouleeswaran PM; Hara T; Sahu V; Kasagi Y; Kikuchi O; Tanaka K; Giroux V; Muir AB; Whelan KA; Ohashi S; Naganuma S; Klein-Szanto AJ; Shinden Y; Sasaki K; Omoto I; Kita Y; Muto M; Bass AJ; Diehl JA; Ginsberg GG; Doki Y; Mori M; Uchikado Y; Arigami T; Avadhani NG; Basu D; Rustgi AK; Natsugoe S
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):73-91. PubMed ID: 30510992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.
    Al-Samadi A; Poor B; Tuomainen K; Liu V; Hyytiäinen A; Suleymanova I; Mesimaki K; Wilkman T; Mäkitie A; Saavalainen P; Salo T
    Exp Cell Res; 2019 Oct; 383(2):111508. PubMed ID: 31356815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
    Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
    BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma.
    Tada H; Takahashi H; Kawabata-Iwakawa R; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Chikamatsu K
    Sci Rep; 2020 Dec; 10(1):21573. PubMed ID: 33299117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.
    Zhang M; Hoyle RG; Ma Z; Sun B; Cai W; Cai H; Xie N; Zhang Y; Hou J; Liu X; Chen D; Kellogg GE; Harada H; Sun Y; Wang C; Li J
    Mol Ther; 2021 Aug; 29(8):2583-2600. PubMed ID: 33794365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids.
    Karakasheva TA; Kijima T; Shimonosono M; Maekawa H; Sahu V; Gabre JT; Cruz-Acuña R; Giroux V; Sangwan V; Whelan KA; Natsugoe S; Yoon AJ; Philipone E; Klein-Szanto AJ; Ginsberg GG; Falk GW; Abrams JA; Que J; Basu D; Ferri L; Diehl JA; Bass AJ; Wang TC; Rustgi AK; Nakagawa H
    Curr Protoc Stem Cell Biol; 2020 Jun; 53(1):e109. PubMed ID: 32294323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tipifarnib as a Precision Therapy for
    Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
    Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.
    Kolenda T; Guglas K; Kopczyńska M; Teresiak A; Bliźniak R; Mackiewicz A; Lamperska K; Mackiewicz J
    Cells; 2019 Apr; 8(4):. PubMed ID: 31010087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.